Skip to main content

Table 7 Biophysical data from available studies, categorized by research type (no. of articles = 10)

From: Shared medical appointments and patient-centered experience: a mixed-methods systematic review

First author, year Model Health cond(s) Sample size (n) Biophysical measures Reported findings (with p-values)
Junling, 2015 CHCC HTN 600 group, 604 control BP SBP decreased significantly in both group (p < 0.001) and control (p = 0.001) from baseline to follow-up, although decreases in group > control.
DBP decreased significantly in group (p = 0.001) but did not decrease significantly in control.
Physical activity
BMI did not change in both.
Increases in physical activity in group (p < 0.001) more remarkable than in control.
Trento, 2001 SMA / GV T2DM 56 group, 56 control HbA1c HbA1c stable in group, worsened in control (p < 0.002).
BMI Tendency toward lower BMI in group (p = 0.06).
HDL HDL cholesterol initially similar in both but later lower in group only (p < 0.05).
Fasting TG Trend toward lower TG in group (p = 0.053).
Trento, 2002 SMA / GV T2DM 56 group, 56 control Dosage of anti-hyperglycemic agents
Body wt, BP and CV risk
Metabolic control:
- HbA1c
- Retinopathy
Dosage of hypoglycemic agents decreased (p < 0.001) among group compared to control.
Body wt (p < 0.001) and BMI (p < 0.001) decreased in group but not in control.
Similar reductions in BP and CV risk in group vs control, but diff significant only for DBP (p < 0.001).
Significant decrease in HbA1c (p < 0.001) in group.
HDL increased (p < 0.001) in group but not in control. Retinopathy progressed less in group (p = 0.009).
Trento, 2004 SMA / GV T2DM (NIDDM) 56 group, 56 control HbA1c
HbA1c remained stable in group but progressively increased among control (p < 0.001).
BMI, HDL, TG and Cr improved over 5 yrs. in group, but not significantly different from control.
Trento, 2005 SMA / GV T2DM 31 group, 31 control HbA1c HbA1c decreased in both, though not significantly.
Lipids (TC, HDL, TG) TC decreased in controls (p < 0.05), while HDL increased in group (p = 0.027).
Body wt, BMI No significant modifications in other clinical variables monitored (body wt, BMI, FBG, insulin dosage, TG, ACR, foot ulcers).
Insulin dosage
Foot ulcers
Trento, 2010 SMA / GV T2DM (NIDDM) 421 group, 394 control FBG
FBG, HbA1c, TC, TG, LDL cholesterol, SBP, DBP, and BMI decreased in group from baseline to year 4 compared to control (p < 0.001, for all measures).
HDL increased in group (p < 0.001).
TC, LDL, HDL, TG Cr did not change significantly in group.
BMI, HbA1c, TG, and Cr increased in control, whereas total, HDL, and LDL cholesterol and SBP did not change and DBP decreased.
Naik, 2011 SMA / GV T2DM 45 group, 42 control HbA1c
Significantly greater improvements in HbA1c immediately following active Intervention and persisted at 1-year follow-up (p = 0.05).
SBP and BMI were only reported at baseline, but not significantly different between both.
Capello, 2008 SMA / GV HTN 58 group (no control) BP Significant effects on SBP and DBP (p < 0.01).
Raballo, 2012 SMA / GV T1DM, T2DM 121 group, 121 control HbA1c
Lipids (TC, HDL, TG)
HbA1c lower in T1DM group than in control (p = 0.001) and not significantly so in T2DM (NS).
Lower HDL in T1DM control (p = 0.002), but no other significant differences among both.
Mixed Methods
Krzywkowski-Mohn, 2008 SMA / GV T2DM 33 group (no control) Diabetic clinical indicators:  
HbA1c Lower HbA1c after group intervention (p < 0.05).
LDL Lower LDL after 18 mos (p < 0.05).
BP No significant diff. in SBP or DBP after 18 mos.
Retinal exam Increase in diabetic eye exams.
Foot exam No diff in diabetic foot exams (96.9% pre + post).
  1. Abbreviations: ACR Albumin/Creatinine ratio, BMI Body mass index, BP Blood pressure, Cr Creatinine, CV Cardiovascular, DBP Diastolic blood pressure, FBG Fasting blood glucose, HbA1c Glycated hemoglobin, HDL High density lipoprotein, HTN Hypertension, LDL Low density lipoprotein, NIDDM Non-insulin dependent diabetes mellitus, SBP Systolic blood pressure, T1DM Diabetes mellitus, type 1, T2DM Diabetes mellitus, type 2, TC Total cholesterol, TG Triglycerides